Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnoea (OSA) through neuromodulation, announced today the appointment of Ben Fear as its UK Director.
With over a decade’s experience in the medical device industry, Ben is leading the UK market release of Nyxoah, which began with the rollout of the Genio system, a breakthrough therapy for obstructive sleep apnoea (OSA).
Olivier Taelman, CEO of Nyxoah said; “We are delighted to welcome Ben to the team at Nyxoah as our UK Director. Ben’s wealth of experience and knowledge is exceptionally valuable and will help us bring innovative breakthrough devices to help those suffering from sleep apnoea across the UK.”
Obstructive Sleep Apnoea (OSA) is the most common sleep-disordered breathing (SDB) condition, with around 8 million people between 30 and 69 years of age suffering from the condition in the UK alone. An estimated 80% of people with OSA in the UK are undiagnosed or untreated. An undiagnosed patient with moderate or severe OSA can cost the NHS twice as much as a patient who is diagnosed and treated.
Nyxoah’s Genio solution is a battery-free hypoglossal neuromodulation stimulation (HGNS) system which is inserted through a single incision under the chin and controlled by a wearable. The first two patients were successfully implanted by Mr. Ryan Chin Taw Cheong, Consultant ENT and Sleep Surgeon at UCLH.
Speaking about his appointment, Ben Fear, UK Director at Nyxoah said; “Nyxoah is very much leading the way in innovative neuromodulation devices for people who suffer from Obstructive Sleep Apnoea. It’s a very exciting opportunity to be able to bring this much needed device to the UK and help millions of people get a good night’s sleep.”
